mercredi 30 octobre 2019

Onco Actu du 30 octobre 2019


1. BIOLOGIE



Caught on Video: Cancer Cells in Act of Cannibalism [NIH Director's Blog]











Could mathematics help to better treat cancer? [Université de Genève]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Case Western Reserve digital-imaging lab advances understanding of which ‘stage 0’ patients are most likely to progress to advanced cancer and may benefit from additional therapy [Case Western Reserve University]











4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers [Genome Web]











5.10 TRAITEMENTS - ESSAIS



PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer [NCI]










5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma [Cellectis]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Merck’s quarterly Keytruda sales soar past $3 billion, but analysts fret over future growth [Fierce Pharma]










5.2.6 PHARMA - BIOTECH



TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma [TG Therapeutics]











TG Therapeutics touts safer PI3Kδ inhibitor as execs tout PhII data, hunt quick OK for a tough niche [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Statement on FDA’s new report regarding root causes and potential solutions to drug shortages [FDA]











U.S. Blames Drug Shortages on Low Prices and a ‘Broken Marketplace’ [NY Times]










5.9 AACR



Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing [Boehringer Ingelheim]











Hey, wait up Amgen and Mirati, Boehringer Ingelheim is joining the KRAS crowd as early success inspires rivals [EndPoints]











5.9.14 AACR - OVAIRE



Ovarian Cancer: Examining the Microenvironment and Mutational Landscapes to Tailor Treatments [Cancer Research Catalyst]











5.9.15 AACR - VADS



Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer [Kura Oncology]











Tipifarnib Shows Promising Clinical Activity in Patients With HRAS-mutant Head and Neck Cancer [AACR]











6. LUTTE CONTRE LES CANCERS



National ASCO Survey Finds Major Gaps in Americans’ Knowledge of Cancer Prevention, E-Cigarettes, and End-of-Life Care [ASCO]











6.1 OBSERVATION



Report Outlines Social Determinants’ Role in Cancer and Public Health [ACS]










6.10 POLITIQUES



Beware the UK government’s Brexit promises [Nature]











6.12 ETHIQUE



The ‘cancer growing in cancer medicine’: pharma money paid to doctors [STAT]










6.9 CONTROVERSES



Johnson & Johnson Says Recalled Baby Powder Doesn’t Have Asbestos [NY Times]